Last updated on November 2019

Safety and Tolerability of MEDI3506 in Healthy Subjects in Subjects With COPD and Healthy Japanese Subjects


Brief description of study

This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.

Detailed Study Description

This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506 administered by either SC or IV routes.

Part I: Single Ascending Doses in Healthy Subjects with a History of Mild Atopy

Part II: Multiple Ascending Doses in Subjects with GOLD I-II COPD

Part III: Single Dose in Healthy Japanese Subjects

Clinical Study Identifier: NCT03096795

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.